Avicanna Stock Performance
| AVCNF Stock | USD 0.19 0.02 11.76% |
The firm shows a Beta (market volatility) of 0.24, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Avicanna's returns are expected to increase less than the market. However, during the bear market, the loss of holding Avicanna is expected to be smaller as well. At this point, Avicanna has a negative expected return of -0.4%. Please make sure to confirm Avicanna's jensen alpha, as well as the relationship between the skewness and day median price , to decide if Avicanna performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Avicanna has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 1.3 M | |
| Total Cashflows From Investing Activities | 760.8 K |
Avicanna |
Avicanna Relative Risk vs. Return Landscape
If you would invest 30.00 in Avicanna on August 28, 2024 and sell it today you would lose (11.00) from holding Avicanna or give up 36.67% of portfolio value over 90 days. Avicanna is currently producing negative expected returns and takes up 8.0706% volatility of returns over 90 trading days. Put another way, 71% of traded otc stocks are less volatile than Avicanna, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Avicanna Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Avicanna's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Avicanna, and traders can use it to determine the average amount a Avicanna's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0498
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AVCNF |
Estimated Market Risk
| 8.07 actual daily | 71 71% of assets are less volatile |
Expected Return
| -0.4 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Avicanna is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Avicanna by adding Avicanna to a well-diversified portfolio.
Avicanna Fundamentals Growth
Avicanna OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Avicanna, and Avicanna fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Avicanna OTC Stock performance.
| Return On Equity | -1.69 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (2.11) % | |||
| Current Valuation | 20.15 M | |||
| Shares Outstanding | 74.52 M | |||
| Price To Book | 9.32 X | |||
| Price To Sales | 4.51 X | |||
| Revenue | 3.27 M | |||
| EBITDA | (15.13 M) | |||
| Cash And Equivalents | 685.94 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 415.83 K | |||
| Debt To Equity | 0.31 % | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (11.66 M) | |||
| Earnings Per Share | (0.26) X | |||
| Total Asset | 22.3 M | |||
About Avicanna Performance
By analyzing Avicanna's fundamental ratios, stakeholders can gain valuable insights into Avicanna's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Avicanna has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Avicanna has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada. Avicanna operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 124 people.Things to note about Avicanna performance evaluation
Checking the ongoing alerts about Avicanna for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Avicanna help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Avicanna generated a negative expected return over the last 90 days | |
| Avicanna has high historical volatility and very poor performance | |
| Avicanna has some characteristics of a very speculative penny stock | |
| Avicanna has accumulated 415.83 K in total debt with debt to equity ratio (D/E) of 0.31, which is about average as compared to similar companies. Avicanna has a current ratio of 0.88, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Avicanna until it has trouble settling it off, either with new capital or with free cash flow. So, Avicanna's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Avicanna sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Avicanna to invest in growth at high rates of return. When we think about Avicanna's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 3.27 M. Net Loss for the year was (16.77 M) with profit before overhead, payroll, taxes, and interest of 2.83 M. | |
| Avicanna has accumulated about 685.94 K in cash with (11.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 23.0% of Avicanna shares are held by company insiders |
- Analyzing Avicanna's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Avicanna's stock is overvalued or undervalued compared to its peers.
- Examining Avicanna's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Avicanna's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Avicanna's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Avicanna's otc stock. These opinions can provide insight into Avicanna's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Avicanna OTC Stock analysis
When running Avicanna's price analysis, check to measure Avicanna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avicanna is operating at the current time. Most of Avicanna's value examination focuses on studying past and present price action to predict the probability of Avicanna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avicanna's price. Additionally, you may evaluate how the addition of Avicanna to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |